An adaptive anti-tumor immune response was evidenced by the slightly decreased percentage of CD4+ helper cells among CD3+ lymphocytes, both in the blood and in the pancreas, but concurrent with a statistically significant increase in the percentage of CD8+ cells in the pancreas. This evidence concerns the gene CD4 and neoplasm.